Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
Teleflex completed enrollment in the BIOMAG-LL Clinical Study, with 102 patients across 14 European centers evaluating 35 mm and 40 mm Freesolve Resorbable Magnesium Scaffolds in long coronary lesions. The single-arm trial's primary endpoint is Target Lesion Failure rate at 12 months, with follow-up extending to 60 months.
Key figures
- Drug Name
- Freesolve Resorbable Magnesium Scaffold (RMS)
- Phase Of Trial
- premarket, single-arm clinical study (BIOMAG-LL)
- Sites
- 14
- Patients enrolled
- 102
- Scaffold lengths mm
- [35,40]
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.